Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30592058 | 1.00 | NEK2 (0.51) | NEK2HTR2CEPHX2HRH3KDM4E | |
| SCHEMBL13116668 | 0.85 | HTR2C (0.56) | HTR2CEPHX2KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6749589 | 0.84 | NEK2 (0.54) | NEK2HTR2CEPHX2HRH3 | |
| SCHEMBL19222134 | 0.79 | NEK2 (0.54) | NEK2KDM4EALDH1A1 | |
| SCHEMBL11361294 | 0.79 | NEK2 (0.54) | NEK2KDM4EALDH1A1 | |
| SCHEMBL122262 | 0.78 | USP2 (0.55) | HTR2CEPHX2 | |
| SCHEMBL2452548 | 0.76 | KDM4E (0.58) | NEK2KDM4EALDH1A1 | |
| SCHEMBL29512947 | 0.76 | KDM4E (0.58) | NEK2KDM4EALDH1A1 | |
| SCHEMBL23561114 | 0.76 | HTR2C (0.49) | HTR2CEPHX2KDM4EALDH1A1 | |
| SCHEMBL121912 | 0.76 | HTR2C (0.49) | HTR2CEPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | NEK2 1418/4885HTR2C 1763/4885EPHX2 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.